JP2003507013A5 - - Google Patents

Download PDF

Info

Publication number
JP2003507013A5
JP2003507013A5 JP2001516899A JP2001516899A JP2003507013A5 JP 2003507013 A5 JP2003507013 A5 JP 2003507013A5 JP 2001516899 A JP2001516899 A JP 2001516899A JP 2001516899 A JP2001516899 A JP 2001516899A JP 2003507013 A5 JP2003507013 A5 JP 2003507013A5
Authority
JP
Japan
Prior art keywords
antibody
rage
pharmaceutical composition
domain
sheet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001516899A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003507013A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/022059 external-priority patent/WO2001012598A2/en
Publication of JP2003507013A publication Critical patent/JP2003507013A/ja
Publication of JP2003507013A5 publication Critical patent/JP2003507013A5/ja
Pending legal-status Critical Current

Links

JP2001516899A 1999-08-13 2000-08-11 βシートフィブリルのRAGEへの結合を阻害する方法及びその結果 Pending JP2003507013A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37421399A 1999-08-13 1999-08-13
US09/374,213 1999-08-13
PCT/US2000/022059 WO2001012598A2 (en) 1999-08-13 2000-08-11 METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF

Publications (2)

Publication Number Publication Date
JP2003507013A JP2003507013A (ja) 2003-02-25
JP2003507013A5 true JP2003507013A5 (cg-RX-API-DMAC7.html) 2007-09-27

Family

ID=23475820

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001516899A Pending JP2003507013A (ja) 1999-08-13 2000-08-11 βシートフィブリルのRAGEへの結合を阻害する方法及びその結果

Country Status (6)

Country Link
US (2) US20080019986A1 (cg-RX-API-DMAC7.html)
EP (1) EP1307219A4 (cg-RX-API-DMAC7.html)
JP (1) JP2003507013A (cg-RX-API-DMAC7.html)
AU (1) AU6766800A (cg-RX-API-DMAC7.html)
CA (1) CA2382095A1 (cg-RX-API-DMAC7.html)
WO (1) WO2001012598A2 (cg-RX-API-DMAC7.html)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7258857B2 (en) * 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US6790443B2 (en) * 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US7101838B2 (en) 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
US6465422B1 (en) * 1998-04-17 2002-10-15 The Trustees Of Columbia University In The City Of New York Method for inhibiting tumor invasion or spreading in a subject
AU765719B2 (en) * 1998-10-06 2003-09-25 Trustees Of Columbia University In The City Of New York, The Extracellular novel rage binding protein (EN-RAGE) and uses thereof
PE20020394A1 (es) 2000-08-18 2002-06-21 Agouron Pharma Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
AU2002213192A1 (en) * 2000-10-13 2002-04-22 The Trustees Of Columbia University In The City Of New York A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
CN1235583C (zh) 2001-03-05 2006-01-11 特兰斯泰克制药公司 用作治疗剂的苯并咪唑衍生物
CA2440042C (en) 2001-03-05 2011-09-27 Transtech Pharma, Inc. Carboxamide derivatives as therapeutic agents
US6815175B2 (en) 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
EP1380290A1 (en) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-beta structure pathway and its therapeutic relevance
MXPA05001758A (es) * 2002-08-16 2005-08-19 Wyeth Corp Composiciones y metodos para el tratamiento de trastornos asociados a receptor para productos finales de glicatacion avanzada (rage).
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US8067371B2 (en) 2003-05-09 2011-11-29 The Trustees Of Columbia University In The City Of New York RAGE G82S-related methods and compositions for treating inflammatory disorders
WO2006012415A2 (en) 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Rage protein derivatives
ES2473587T3 (es) 2004-08-03 2014-07-07 Transtech Pharma, Inc. Proteínas de fusión de RAGE y métodos de uso
EP1776459A1 (en) * 2004-08-03 2007-04-25 Transtech Pharma, Inc. Rage fusion proteins and methods of use
EP1869464A4 (en) * 2005-03-17 2009-12-02 Univ Columbia RAGE-DIAPHANOUS INTERACTION AND CORRESPONDING COMPOSITIONS AND METHODS
EP2386861A3 (en) 2005-07-13 2012-07-18 Crossbeta Biosciences B.V. Cross-ß structure binding compounds
US8114832B2 (en) 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
EP1963786B1 (en) * 2005-12-23 2013-07-24 GCoder Systems AB Positioning pattern
WO2007094926A2 (en) * 2006-02-09 2007-08-23 Transtech Pharma, Inc. Rage fusion proteins and methods of use
MX2008011933A (es) * 2006-03-21 2008-12-18 Wyeth Corp Metodos y composiciones para antagonismo de rage.
EA017291B1 (ru) 2006-05-05 2012-11-30 Транстек Фарма, Инк. Белки слияния на основе rage, их композиции и способы их применения
WO2008100470A2 (en) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
US20100254983A1 (en) * 2007-06-07 2010-10-07 Ann Marie Schmidt Uses of rage antagonists for treating obesity and related diseases
US8398977B2 (en) 2007-06-14 2013-03-19 Galactica Pharmaceuticals, Inc. Rage fusion proteins
CN102089430B (zh) * 2008-05-09 2015-02-04 Abbvie公司 针对渐进性糖化终极产物受体(rage)的抗体及其用途
CN102037119B (zh) 2008-05-23 2015-06-24 Siwa有限公司 促进再生的方法、组合物及设备
US9034341B2 (en) 2009-04-20 2015-05-19 Transtech Pharma, Llc Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
CA2772797C (en) 2009-09-30 2018-09-25 Transtech Pharma, Inc. Substituted imidazole derivatives
TWI510241B (zh) 2010-02-18 2015-12-01 Vtv Therapeutice Llc 苯基-雜芳基衍生物及其使用方法
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
WO2012047629A2 (en) 2010-09-27 2012-04-12 Siwa Corporation Selective removal of age-modified cells for treatment of ather0sclerosis
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
US9309728B2 (en) * 2012-05-14 2016-04-12 Nabors Drilling International Limited Drilling rig employing tubular handling device
KR20150064743A (ko) 2012-10-05 2015-06-11 트랜스테크 파르마 엘엘씨 경도 및 중등도 알츠하이머 병의 치료
CN105143859B (zh) * 2013-03-14 2018-12-04 惠普发展公司,有限责任合伙企业 检测物质的设备和制造这样的设备的方法
CA2925757A1 (en) * 2013-09-30 2015-04-02 Cornell University Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity
AU2015318036B2 (en) 2014-09-19 2021-07-01 Siwa Corporation Anti-AGE antibodies for treating inflammation and auto-immune disorders
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
IL283726B2 (en) 2016-02-19 2025-05-01 Siwa Corp A preparation containing an antibody to advanced glycation end products (AGE) for use in the treatment of breast cancer
EP3443007A1 (en) 2016-04-15 2019-02-20 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
US11213585B2 (en) 2016-06-23 2022-01-04 Siwa Corporation Vaccines for use in treating various diseases and disorders
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
BR112019021471A2 (pt) 2017-04-13 2020-05-12 Siwa Corporation Anticorpo monoclonal humanizado de produto final da glicação avançada
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190823A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
JP7464591B2 (ja) 2018-10-10 2024-04-09 ブイティーブイ・セラピューティクス・エルエルシー [3-(4-{2-ブチル-1-[4-(4-クロロ-フェノキシ)-フェニル]-1h-イミダゾール-4-イル}-フェノキシ)-プロピル]-ジエチル-アミンの代謝産物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
JPH09511492A (ja) * 1994-02-03 1997-11-18 ザ ピコワー インスティテュート フォア メディカル リサーチ アミロイドーシスの前進性グリコシル化終末産物仲介モジュレーション用組成物及び方法
WO1997026913A1 (en) * 1996-01-26 1997-07-31 The Trustees Of Columbia University In The City Of New York A POLYPEPTIDE FROM LUNG EXTRACT WHICH BINDS AMYLOID-β PEPTIDE
US5864018A (en) * 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
WO1997039121A1 (en) * 1996-04-16 1997-10-23 Schering Aktiengesellschaft Advanced glycosylation end-product receptor peptides and uses therefor
US6555651B2 (en) * 1997-10-09 2003-04-29 The Trustees Of Columbia University In The City Of New York Ligand binding site of rage and uses thereof
US6790443B2 (en) * 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US6100098A (en) * 1997-02-18 2000-08-08 Mcgill University Anti-AGE IgG and uses thereof for the diagnosis of severe disease
SI0994728T1 (sl) * 1997-04-09 2009-02-28 Intellect Neurosciences Inc Rekombinantna protitelesa, specifična za beta-amiloidne konce, kodirana z DNA ter postopki za njihovo uporabo
US7101838B2 (en) * 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts

Similar Documents

Publication Publication Date Title
WO2005035584A8 (en) Fully human antibodies against human 4-1bb (cd137)
JP2004511430A5 (cg-RX-API-DMAC7.html)
JP2006512316A5 (cg-RX-API-DMAC7.html)
WO2008036341A3 (en) Compositions and methods relating to glucagon receptor antibodies
WO2003016467A3 (en) Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass
JP2003503454A5 (cg-RX-API-DMAC7.html)
WO2005011599A3 (en) Antibodies specific for toxic amyloid beta protein oligomers
WO2006029879A3 (en) Anti-ox40l antibodies
WO2004010947A3 (en) Humanized antibodies against human 4-1bb
EA200300628A1 (ru) Соединения, специфические к аденозиновому a, aи aрецептору, и их применение
JP2002533680A5 (cg-RX-API-DMAC7.html)
JP2003520232A5 (cg-RX-API-DMAC7.html)
ATE389404T1 (de) Kappa-opioid-rezeptor-liganden
BR0108471A (pt) Objeto pré-formado para liberar um agente ativo a um paciente, e, processos de formação de um objeto pré-formado para liberar um agente e de liberação de um agente ativo a um paciente
WO2002039998A3 (en) Methods and compositions for regulating memory consolidation
DK1216707T3 (da) Fremgangsmåde til screening af ligandmolekyler, der specifikt binder til NEP-bindingsstederne for QHNPR-pentapeptidet
NO20023551L (no) Ibuprofen-inneholdende aktivt middel-preparat
WO2008013948A3 (en) Tyrosine phosphorylation sites
JP2004501204A5 (cg-RX-API-DMAC7.html)
WO2008054597A3 (en) Tyrosine phosphorylation sites
JP2023541928A5 (cg-RX-API-DMAC7.html)
WO2008100563A3 (en) Compositions and methods for diagnosing and treating cancer
WO2006009525A3 (en) P. aeruginosa mucoid exopolysaccharide specific binding peptides
WO2003026700A3 (fr) Compositions pour la vectorisation d'anticorps a travers la barriere hematoencephalique et leur utilisation pour le diagnostic ou le traitement des maladies du systeme nerveux central
ATE414714T1 (de) Polypeptide-k erhalten vom momordica charantia and eine methode für sein extraktion